Neurocrine Biosciences
NBIX
NBIX
267 hedge funds and large institutions have $7.29B invested in Neurocrine Biosciences in 2017 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 82 increasing their positions, 93 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
2.62% less ownership
Funds ownership: 108.79% → 106.18% (-2.6%)
12% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 93
22% less call options, than puts
Call options by funds: $30.8M | Put options by funds: $39.6M
Holders
267
Holding in Top 10
7
Calls
$30.8M
Puts
$39.6M
Top Buyers
| 1 | +$75.2M | |
| 2 | +$35.3M | |
| 3 | +$32.4M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$30.1M |
| 5 |
Renaissance Technologies
New York
|
+$30M |
Top Sellers
| 1 | -$75.8M | |
| 2 | -$43.6M | |
| 3 | -$42.4M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$37.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$36.4M |